CIBC Boosts Knight Therapeutics Inc (GUD) Price Target to C$9.80
Knight Therapeutics Inc (TSE:GUD) had its target price boosted by CIBC from C$9.50 to C$9.80 in a research note published on Friday morning, StockTargetPrices.com reports.
Separately, Scotiabank restated an outperform rating and issued a C$9.50 price target on shares of Knight Therapeutics in a research report on Monday, July 18th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Knight Therapeutics has a consensus rating of Buy and a consensus price target of C$9.83.
Knight Therapeutics (TSE:GUD) opened at 9.78 on Friday. The firm’s 50-day moving average is $9.20 and its 200 day moving average is $8.65. Knight Therapeutics has a 52-week low of $5.89 and a 52-week high of $9.86. The stock has a market capitalization of $1.30 billion and a PE ratio of 68.87.
About Knight Therapeutics
Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally.
Receive News & Stock Ratings for Knight Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics Inc and related stocks with our FREE daily email newsletter.